Novo Nordisk A/S has unveiled promising results from its phase 3 REAL8 basket study, showcasing the efficacy and safety of once-weekly Sogroya (somapacitan) in children with various growth disorders. The study, part of the broader REAL clinical trial, compared the long-acting growth hormone to the once-daily Norditropin (somatropin), revealing comparable clinical outcomes and safety profiles after 52 weeks of treatment. This marks a significant step forward in reducing the treatment burden for children and their families.

The REAL8 trial focused on children born small for gestational age (SGA), those with Noonan syndrome (NS), and individuals with idiopathic short stature (ISS). Notably, Sogroya not only matched the efficacy of daily growth hormone treatments but also demonstrated superiority in certain subgroups, including children with NS and those born SGA receiving lower doses of daily growth hormone. These findings highlight the potential of Sogroya to offer a more convenient and equally effective treatment option for pediatric growth disorders.

Adherence to treatment is a critical challenge in managing growth disorders, with the burden of daily injections often leading to decreased compliance. The introduction of a once-weekly treatment like Sogroya could significantly alleviate this issue, improving treatment outcomes and quality of life for affected children. Novo Nordisk's commitment to innovation in this space is evident, as the company seeks to address unmet needs in pediatric endocrinology.

With regulatory submissions for Sogroya in the European Union and the U.S. based on the REAL8 and REAL9 studies, the future looks promising for this novel treatment. As the medical community awaits further developments, the data presented at the joint Congress of ESPE and ESE underscore the potential of Sogroya to transform the treatment landscape for children with growth disorders, offering hope for easier management and better adherence to therapy.

Mjällby AIF stands on the brink of securing the Swedish Allsvenskan championship, with their fate potentially decided during Sunday's heated Stockholm derby between Hammarby and AIK. The southern Swedish club could clinch the title without even playing if Hammarby drops points against their city rivals. This unprecedented scenario has created intense anticipation across Swedish football as the season reaches its dramatic conclusion.

In Bromölla, Mjällby's supporter club Sillastrybarna gathered at a restaurant to watch the Stockholm derby together, reflecting the nervous excitement surrounding the potential championship. "The feeling is that anything could happen today, but we're satisfied either way," said Kristofer Rasmusson, vice chairman of Sillastrybarna. The supporters acknowledged that while winning the title during another team's match would be unusual, it would still represent a remarkable achievement for the club.

Should Hammarby secure victory against AIK on Sunday, Mjällby's championship aspirations would extend to Monday's away match against IFK Göteborg. In that scenario, Mjällby would need to defeat the Gothenburg side to claim the SM-gold. Maximilian Damm, who is live-reporting on Mjällby's title chase, expressed confidence in the team's abilities, stating, "As soon as they get to play a match. That is, on Monday against IFK Göteborg away. It's hard not to be impressed by how MAIF approaches matches, and there's no reason not to believe they won't win on Monday."

The Monday encounter against IFK Göteborg presents its own challenges, with historical data showing low-scoring affairs between the two clubs. The last five meetings have produced just one goal per match, with Mjällby holding three victories to IFK's two. Despite this history, both teams have significant motivation - Mjällby for the championship and IFK Göteborg for European qualification spots and honor. The match kicks off Monday at 19:10, potentially crowning a new Swedish champion.